Purpose: The purpose of the study was to evaluate the usefulness of power law spectral analysis on mammographic parenchymal patterns in breast cancer risk assessment. Materials and Methods: Mammograms from 172 subjects (30 women with the BRCA1/BRCA2 gene mutation and 142 low-risk women) were retrospectively collected and digitized. Because age is a very important risk factor, 60 low-risk women were randomly selected from the 142 low-risk subjects and were age matched to the 30 gene mutation carriers. Regions of interest were manually selected from the central breast region behind the nipple of these digitized mammograms and subsequently used in power spectral analysis. The power law spectrum of the form \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$P\left( f \right) = {B \mathord{\left/ {\vphantom {B {f^\beta }}} \right. \kern-\nulldelimiterspace} {f^\beta }}$$\end{document} was evaluated for the mammographic patterns. The performance of exponent β as a decision variable for differentiating between gene mutation carriers and low-risk women was assessed using receiver operating characteristic analysis for both the entire database and the age-matched subset. Results: Power spectral analysis of mammograms demonstrated a statistically significant difference between the 30 BRCA1/BRCA2 gene mutation carriers and the 142 low risk women with an average β values of 2.92 (±0.28) and 2.47(±0.20), respectively. An Az value of 0.90 was achieved in distinguishing between gene mutation carriers and low-risk women in the entire database, with an Az value of 0.89 being achieved on the age-matched subset. Conclusions: The BRCA1/BRCA2 gene mutation carriers and low-risk women have different mammographic parenchymal patterns. It is expected that women identified as high risk by computerized feature analyses might potentially be more aggressively screened for breast cancer.
展开▼
